DUBLIN--(BUSINESS WIRE)--The "Atypical Hemolytic Uremic Syndrome(aHUS) - Market Insight, Epidemiology and Market Forecast -2030" report has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the Atypical Hemolytic Uremic Syndrome, historical and forecasted epidemiology as well as the Atypical Hemolytic Uremic Syndrome market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Atypical Hemolytic Uremic Syndrome market report provides current treatment practices, emerging drugs, Atypical Hemolytic Uremic Syndrome market share of the individual therapies, current and forecasted Atypical Hemolytic Uremic Syndrome market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Atypical Hemolytic Uremic Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Companies Mentioned
- Alexion Pharmaceuticals
- Omeros Corporation
- Novartis Pharmaceuticals
- Hoffmann-La Roche
- Chugai Pharmaceutical
Key Findings
The Atypical Hemolytic Uremic Syndrome (aHUS) market size in the 7MM is expected to change during the study period 2018-2030. The therapeutic market of Atypical Hemolytic Uremic Syndrome in the seven major markets is expected to increase during the study period (2018-2030) with a CAGR of 3.3%. According to the estimates, the highest market size of Atypical Hemolytic Uremic Syndrome is found in the United States followed by Germany.
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the Atypical Hemolytic Uremic Syndrome market.
- To understand the future market competition in the Atypical Hemolytic Uremic Syndrome market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Atypical Hemolytic Uremic Syndrome in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the Atypical Hemolytic Uremic Syndrome market.
- To understand the future market competition in the Atypical Hemolytic Uremic Syndrome market.
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Atypical Hemolytic Uremic Syndrome (aHUS) Market Overview at a Glance
4. Executive Summary of Atypical Hemolytic Uremic Syndrome (aHUS)
4.1. Key Events
5. Epidemiology and Market Methodology
6. Disease Background and Overview
6.1. Introduction
6.2. Types of Hemolytic Uremic Syndrome
6.3. Risk Factors and Causes of Atypical Hemolytic Uremic Syndrome
6.4. Signs and Symptoms of Atypical Hemolytic Uremic Syndrome
6.5. Pathophysiology of Atypical Hemolytic Uremic Syndrome
6.6. Complement Protein Mutations
6.7. Clinical Manifestations of Atypical Hemolytic Uremic Syndrome
7. Diagnosis and Differential Diagnosis of Atypical Hemolytic Uremic Syndrome
7.1. Diagnostic Algorithm of Atypical Hemolytic Uremic Syndrome
7.2. Blood Tests
7.3. Specific Testing
7.4. Genetic Testing
7.5. Differential Diagnosis
8. Diagnostic Guidelines
8.1. The Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society
8.2. Clinical Practice Guidelines for the management of atypical Hemolytic Uremic Syndrome in the United Kingdom
9. Current Treatment Practices of Atypical Hemolytic Uremic Syndrome
9.1. Treatment Algorithm of Atypical hemolytic uremic syndrome
9.1.1. Plasma Exchange
9.1.2. Eculizumab
9.1.3. Ravulizumab
9.1.4. Kidney Transplant
9.1.5. Liver transplantation
10. Treatment Guidelines
10.1. The European Rare Kidney Disease Reference Network guidelines to the management of atypical hemolytic uremic syndrome in children
10.2. Clinical Practice Guidelines for the management of atypical Hemolytic Uremic Syndrome in the United Kingdom
10.3. National Institute for Health and Research
11. Conclusion
12. Epidemiology and Patient Population
12.1. Key Findings
12.2. Epidemiology of Atypical Hemolytic Uremia Syndrome
12.3. Epidemiology Scenario
12.3.1. Total Prevalent Cases of Atypical Hemolytic Uremia Syndrome
12.3.2. Total Diagnosed Cases of Atypical Hemolytic Uremia Syndrome
12.3.3. Total Age group-specific Cases of Atypical Hemolytic Uremia Syndrome
12.3.4. Total Treated Cases of Atypical Hemolytic Uremia Syndrome
13. Patient Journey
14. Key Endpoints in Atypical Hemolytic Uremic Syndrome (aHUS) Clinical Trials
15. Marketed Therapies
15.1. Soliris (Eculizumab): Alexion Pharmaceuticals
15.1.1. Drug Description
15.1.2. Regulatory Milestones
15.1.3. Other Developmental Activities
15.1.4. Pivotal Clinical Trial
15.2. Ultomiris (Ravulizumab): Alexion Pharmaceuticals
15.2.1. Drug Description
15.2.2. Regulatory Milestones
15.2.3. Other Developmental Activities
15.2.4. Pivotal Clinical Trial
15.2.5. Ongoing Current Pipeline Activity
16. Emerging Therapies
16.1. Narsoplimab (OMS721): Omeros Corporation
16.1.1. Product Description
16.1.2. Other Developmental Activities
16.1.3. Clinical Developmental Activities
16.1.4. Safety and Efficacy
16.2. Iptacopan (LNP 023): Novartis Pharmaceuticals
16.2.1. Product Description
16.2.2. Clinical Developmental Activities
16.3. Crovalimab (RG6107; SKY59): Hoffmann-La Roche/Chugai Pharmaceutical
16.3.1. Product Description
16.3.2. Clinical Developmental Activities
17. Atypical Hemolytic Uremic Syndrome: 7 Major Market Analysis
18. Market Access and Reimbursement
19. KOL Views
20. Market Drivers
21. Market Barriers
22. SWOT Analysis
23. Unmet Needs
24. Appendix
25. Disclaimer
26. About the Publisher
For more information about this report visit https://www.researchandmarkets.com/r/hi7rxa
